Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of bortezomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in elderly patients with newly diagnosed multiple myeloma
KCT0004508Phase 2Active, not recruiting
- Sponsor
- Samsung Medical Center
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, lenalidomide, dexamethasone in multiple myeloma (MM), sponsored by Samsung Medical Center. Started Aug 2020; status: active, not recruiting.
02
Drugs
bortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0004508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004508.